戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  with chronic tricuspid regurgitation due to acquired heart disease.
2 ld it be required for the later treatment of acquired heart disease.
3  of infants and children with congenital and acquired heart disease.
4 es for cardiac repair in both congenital and acquired heart disease.
5 ds of pediatric patients with congenital and acquired heart disease.
6 often has mechanisms different from those in acquired heart disease.
7 cy in patients with underlying congenital or acquired heart disease.
8      Most women had associated congenital or acquired heart disease.
9 romboembolism in children with congenital or acquired heart disease.
10  palliative care in pediatric congenital and acquired heart disease.
11  therapeutic implications for congenital and acquired heart diseases.
12 generative therapies targeting congenital or acquired heart diseases.
13 stem cell-based therapies for congenital and acquired heart diseases.
14 ucidating the pathogenesis of congenital and acquired heart diseases.
15 lopment of novel therapies for congenital or acquired heart diseases.
16 tential of targeting cardiac microtubules in acquired heart diseases.
17     Kawasaki disease is the leading cause of acquired heart disease among children in the USA.
18 ry artery aneurysms, is the leading cause of acquired heart disease among children.
19 rrantly regulated in a large-animal model of acquired heart disease and in failing human myocardium.
20                                              Acquired heart diseases and their associated risk factor
21 form the treatment of congenital, as well as acquired, heart disease and likewise would enable develo
22        Furthermore, genetic contributions to acquired heart diseases are increasingly being recognize
23 ht ventricle (RV) is of lesser importance in acquired heart disease, but its role is of increasing im
24 though survival for pediatric congenital and acquired heart disease has tremendously improved in rece
25 his document, a state-of-the-art overview of acquired heart disease in ACHD patients and guidance on
26 uidance for the prevention and management of acquired heart disease in ACHD patients is currently not
27 phan disease, its role as a leading cause of acquired heart disease in children has led to significan
28 asaki Disease (KD), the most common cause of acquired heart disease in children in developed countrie
29 ported worldwide and is the leading cause of acquired heart disease in children in developed countrie
30          Although KD is the leading cause of acquired heart disease in children in developed nations,
31 se is recognized as the most common cause of acquired heart disease in children in the developed worl
32 asaki disease (KD), the most common cause of acquired heart disease in children, can be easily missed
33 aki disease (KD) is the most common cause of acquired heart disease in children.
34 cute rheumatic fever as the leading cause of acquired heart disease in children.
35 Kawasaki syndrome (KS) is the major cause of acquired heart disease in children.
36 disease has emerged as an important cause of acquired heart disease in children.
37 ns administer appropriate therapy to prevent acquired heart disease in children.
38 ediatric vasculitis and the leading cause of acquired heart disease in children.
39   Kawasaki disease, the most common cause of acquired heart disease in developed countries, is a self
40 ildren <5 years old, is the leading cause of acquired heart disease in developed countries, with the
41 sease (KD) is the leading cause of childhood acquired heart disease in developed nations and can resu
42 tion, KD has become the most common cause of acquired heart disease in the pediatric age group in dev
43                   To describe congenital and acquired heart diseases in a Spanish cohort of adults wi
44         Although most arrhythmias are due to acquired heart disease, inherited channelopathies and ca
45 heter therapy in children with congenital or acquired heart disease is a challenging, innovative, and
46               Finally, diastolic function in acquired heart disease or with systemic disease in the c
47 covery of LV ejection fraction (LVEF) in the acquired heart disease population.
48  on LVSD are well described in patients with acquired heart disease, such data are sparse in adults w
49 st, maternal mortality is high in women with acquired heart disease that presents during pregnancy (s
50 is a final common pathology in inherited and acquired heart diseases that causes cardiac electrical a
51 hildren and young adults with congenital and acquired heart disease, the public health burden and hea
52 al child and in the child with congenital or acquired heart disease, was a primary focus of pediatric
53 ges to the care team, and unlike adults with acquired heart disease who progress to severe heart fail